TCM
JAZZ icon

Tekla Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Tekla Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-281
Closed -$46K – 118
2014
Q4 		$46K Buy
+281
New +$46.6K ﹤0.01% 93

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tekla Capital Management's JAZZ Position: Q2 2023 in Review

Tekla Capital Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2023 at 147,779 shares worth $18.3M. The position accounts for 0.72% of the portfolio, ranked #39.

Tekla Capital Management first reported a position in JAZZ in Q2 2014 and has held it in 35 quarters since. The position peaked at $48.1M in Q1 2017. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

  • Tekla Capital Management held 147,779 shares of Jazz Pharmaceuticals worth $18.3M as of Q2 2023.
  • Tekla Capital Management left its Jazz Pharmaceuticals share count unchanged in Q2 2023.
  • Jazz Pharmaceuticals made up 0.72% of Tekla Capital Management's portfolio in Q2 2023, its #39 holding.
  • Tekla Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2014 and has held it in 35 quarters since.
  • Tekla Capital Management's Jazz Pharmaceuticals position peaked at $48.1M in Q1 2017.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.